Compare Abbott Laboratories (ABT) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs DuPont de Nemours Inc — how do they compare? Abbott Laboratories trades at $95.15 (market cap $166.94B), while DuPont de Nemours Inc trades at $136.69 (market cap $18.85B). The key difference: Abbott Laboratories is far larger — about 8.9× DuPont de Nemours Inc's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | DD | |
|---|---|---|
Market Cap | $166.94B | $18.85B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $154.59 |
52-Week Low | $82.57 | $87.72 |
Enterprise Value | $193.69B | $21.31B |
Dividend Yield | 2.63% | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
DuPont (DD) trades at $139.61, down 0.21% on the day, with a bearish technical signal but strong analyst support. Recent earnings have consistently beaten estimates, including Q1 2026 EPS of $1.65 versus $1.44 expected, though revenue declined to $6.85B in 2025. The company executed a 3:1 reverse stock split in June 2026 and maintains dividend payments, highlighting financial restructuring efforts amid mixed segment performance.
The outlook is cautiously optimistic with a consensus price target of $227.20, implying significant upside, but risks include persistent net losses, weak Q3 guidance concerns, and macroeconomic pressures on industrial segments. Investment appeal hinges on margin improvement and successful portfolio repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
